Abstract
A biokinetic model was constructed to evaluate and optimize various intraperitoneal radioimmunotherapies for micrometastatic tumors. The model was used to calculate the absorbed dose to both anticipated microtumors and critical healthy organs and demonstrated how intraperitoneal targeted radiotherapy can be optimized to maximize the ratio between them. The various transport mechanisms responsible for the biokinetics of intraperitoneally infused radiolabeled monoclonal antibodies (mAbs) were modeled using a software package. Data from the literature were complemented by pharmacokinetic data derived from our clinical phase I study to set parameter values. Results using the β-emitters (188)Re, (177)Lu, and (90)Y and the α-emitters (211)At, (213)Bi, and (212)Pb were compared. The effects of improving the specific activity, prolonging residence time by introducing an osmotic agent, and varying the activity concentration of the infused agent were investigated. According to the model, a 1.7-L infused saline volume will decrease by 0.3 mL/min because of lymphatic drainage and by 0.7 mL/min because of the transcapillary convective component. The addition of an osmotic agent serves to lower the radiation dose to the bone marrow. Clinical...Continue Reading
References
Jan 1, 1995·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·F CrippaE Bombardieri
Jul 19, 2000·Circulation·S GalatiusJ Kastrup
Sep 17, 2002·Kidney International. Supplement·James B MoberlyMarsha Wolfson
Mar 6, 2004·Medical Physics·Stig PalmLars Jacobsson
Feb 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·René H VerheijenMichael V Seiden
May 23, 2006·American Journal of Physiology. Heart and Circulatory Physiology·J Stachowska-PietkaB Lindholm
Mar 14, 2007·International Journal of Cancer. Journal International Du Cancer·Angèle L OeiLeon F Massuger
Jun 16, 2009·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Håkan AnderssonRagnar Hultborn
Mar 15, 2012·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Jazmin SchwartzJoseph A O'Donoghue
Sep 21, 2012·Clinical Pharmacology and Therapeutics·P D Garzone, A J Atkinson
Apr 23, 2013·Nuclear Medicine and Biology·Kwamena E BaidooMartin W Brechbiel
Jun 14, 2013·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Nicolas ChouinTom Bäck
Nov 13, 2013·Archives of Medical Research·Jacek Waniewski
Jul 12, 2014·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Behrooz VaziriUNKNOWN SNMMI MIRD Committee
Aug 1, 2015·Pharmaceuticals·Diane E MilenicMartin W Brechbiel
Oct 16, 2015·International Journal of Radiation Oncology, Biology, Physics·Elin CederkrantzPer Albertsson
Citations
Jan 23, 2016·Bioconjugate Chemistry·Emma H K AneheimSture Lindegren
Jan 20, 2017·The British Journal of Radiology·Matthew GardnerElizabeth A Larkin
Mar 18, 2017·Radiation Oncology·Andrew B SatterleeLeaf Huang
Feb 23, 2020·Cancer Biotherapy & Radiopharmaceuticals·Sture LindegrenEmma Aneheim
Mar 7, 2019·Current Medicinal Chemistry·Benjamin B KastenDonald J Buchsbaum
May 4, 2017·BMC Cancer·Kristina LevanKarin Sundfeldt
Nov 7, 2019·Scientific Reports·Emma AneheimSture Lindegren
Apr 26, 2017·EJNMMI Research·Anna Gustafsson-LutzSture Lindegren
Jun 20, 2020·Cancer Biotherapy & Radiopharmaceuticals·Francisco D C Guerra LiberalKevin M Prise
Sep 29, 2020·Translational Oncology·Stig PalmPer Albertsson
Jan 21, 2017·Nuclear Medicine and Biology·Benjamin B KastenDonald J Buchsbaum
Feb 8, 2018·Nuclear Medicine and Biology·Benjamin B KastenDonald J Buchsbaum
Jan 27, 2019·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Andreas HallqvistPer Albertsson
Nov 28, 2017·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Stig PalmPer Albertsson